WAY-855 | 482377-92-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: WAY-855
• 英文别名: 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid；(-)-(1R*,2R*,3R*,4S*,6S*)-3-aminotricyclo[2.2.1.02.6]heptane-1,3-dicarboxylic acid；Tricyclo[2.2.1.02,6]heptane-1,3-dicarboxylic acid, 3-amino-,(1R,2R,3R,4S,6S)-rel-；3-aminotricyclo[2.2.1.02,6]heptane-1,3-dicarboxylic acid
• CAS: 482377-92-4
• 化学式: C₉H₁₁NO₄
• 分子量: 197.191
• InChiKey: KETJIAAJBCULKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• 3-alkylaryl aspartate compounds and their use for selective enhancement of synaptic transmission
  申请人：Esslinger S. Christopher

  公开号：US20070142467A1

  公开（公告）日：2007-06-21

  The present invention provides an L-aspartate derivative compound represented by the following structure wherein Ar represents an aromatic group; L represents a linking moiety; R represents hydrogen, alkyl, aryl, or heteroaryl; and indicates that the stereochemistry at the 3-position can be R or S. The compounds of the invention are useful for selectively inhibiting EAAT3 and for enhancing synaptic transmission. Additionally, the inventive compounds can be used to treat a patient suffering from Alzheimers disease or a neuropathy or a neurodegenerative disease in which L-glutamate transporter activity is involved in the onset of the disease.

  本发明提供了一种由以下结构表示的L-天冬氨酸衍生物化合物 其中Ar代表芳香基团；L代表连接基团；R代表氢、烷基、芳基或杂环芳基；和 表示3位的立体化学可以是R或S。本发明的化合物对选择性抑制EAAT3和增强突触传递具有用处。此外，这些创新性化合物可用于治疗患有阿尔茨海默病或神经病或神经退行性疾病的患者，其中L-谷氨酸转运蛋白活性参与了疾病的发病。
• Bridged tricyclid analogs of 2-(carboxycyclopropyl)glycine
  申请人：Wyeth

  公开号：US20030018065A1

  公开（公告）日：2003-01-23

  This invention provides processes for preparing a group of novel bridged tricyclic compounds having the formula: 1 wherein X is (CH 2 ) n , O, S, SO, SO 2 or CR 1 R 2 ; n is 1 or 2; and R 1 and R 2 are, independently, hydrogen, halogen, hydroxy, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or R 1 and R 2 , taken together with the carbon to which they are attached, form cycloalkyl of three to six carbon atoms, an alkylidene of up to six carbon atoms or a carbonyl.

  这项发明提供了制备一组新型桥接三环化合物的方法，其化学式为：其中X为(CH2)n，O，S，SO，SO2或CR1R2；n为1或2；R1和R2独立地为氢、卤素、羟基、一至六个碳原子的烷基、一至六个碳原子的烷氧基，或者R1和R2与它们连接的碳原子一起形成三至六个碳原子的环烷基、最多六个碳原子的烷基亚甲基或羰基。
• [EN] STEREOISOMERS OF 3-AMINOTRICYCLO[2.2.1.0(2,6)]HEPTANE-1,3-DICARBOXYLIC ACID<br/>[FR] STEREO-ISOMERES D'ACIDE 3-AMINOTRICYCLO[2.2.1.0(2,6)]HEPTANE-1,3-DICARBOXYLIQUE
  申请人：WYETH CORP

  公开号：WO2003002513A1

  公开（公告）日：2003-01-09

  This invention provides a process for the preparation of all four stereoisomers of formula (I) or a pharmaceutically acceptable salt thereof, which may be represented by the following structures:.

  该发明提供了一种制备公式（I）的所有四个立体异构体或其药学上可接受的盐的过程，其可以用以下结构表示：
• [EN] PROCESS FOR PREPRARING OF BRIDGED TRICYCLIC ANALOGS OF 2-(CARBOXYCYCLOPROPYL)GLYCINE<br/>[FR] PROCEDE DE PREPARATION D'ANALOGUES TRICYCLIQUES PONTES DE 2-(CARBOXYCYCLOPROPYL)GLYCINE
  申请人：WYETH CORP

  公开号：WO2003002516A1

  公开（公告）日：2003-01-09

  This invention provides processes for preparing a group of novel bridged tricyclic compounds having formula (I), wherein X is (CH2)n,O, S, SO, SO2 or CR1R2, n is 1 or 2, and R?1 and R2¿ are, independently, hydrogen, halogen, hydroxy, alkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, or R?1 and R2¿, taken together with the carbon to which they are attached, form cycloalkyl of three to six carbon atoms, an alkylidene of up to six carbon atoms or a carbonyl.

  该发明提供了制备一组新型桥接三环化合物的过程，其化学式为(I)，其中X为(CH2)n、O、S、SO、SO2或CR1R2，n为1或2，R?1和R2¿独立地为氢、卤素、羟基、一至六个碳原子的烷基、一至六个碳原子的烷氧基，或R?1和R2¿与它们附着的碳一起形成三至六个碳原子的环烷基、长达六个碳原子的烷基或一个羰基。
• [EN] BRIDGED TRICYCLIC ANALOGS OF 2-(CARBOXYCYCLOPROPYL)GLYCINE AS INHIBITORS OF GLUTAMATE TRANSPORT<br/>[FR] ANALOGUES TRICYCLIQUES PONTES DE 2-(CARBOXYCYCLOPROPYL)GLYCINE EN TANT QU'INHIBITEURS DE TRANSPORT DE GLUTAMATE
  申请人：WYETH CORP

  公开号：WO2003002515A1

  公开（公告）日：2003-01-09

  This invention provides compounds of formula (I), wherein X is (CH2)n, O, S, SO, SO2, or CR1R2; n is 1 or 2; R?1 and R2¿ H, halogen, hydroxy, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or R?1 and R2¿, taken together form cycloakyl of 3 to 6 carbon atoms, an alkylidene of up to 6 carbon atoms or a carbonyl; R?3, R4 and R5¿ are H or alkyl of 1 to 6 carbon atoms; Z is H, alkyl of 1 to 6 carbon atoms, alkynoyl of 1 to 6 carbon atoms or alkoxycarbonyl of 2 to 7 carbon atoms; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods for their use in treating or preventing characterized by glutamate hypofunction, including schizophrenia, schizoaffective disorder and schizophreniform disorder, and for the treatment of cognitive deficits due to aging, stroke, Alzheimer's disease or other neurodegenerative diseases.

  本发明提供了式(I)的化合物，其中X为(CH2)n，O，S，SO，SO2或CR1R2; n为1或2; R?1和R2¿为H，卤素，羟基，1至6个碳原子的烷基，1至6个碳原子的烷氧基，或者R?1和R2¿结合形成3至6个碳原子的环烷基，最多6个碳原子的烷基或羰基; R?3，R4和R5¿为H或1至6个碳原子的烷基; Z为H，1至6个碳原子的烷基，1至6个碳原子的炔酰基或2至7个碳原子的烷氧羰基; 或其药学上可接受的盐，以及在治疗或预防谷氨酸低功能所表现的精神分裂症、情感性精神障碍和类精神分裂障碍，以及由于衰老、中风、阿尔茨海默病或其他神经退行性疾病引起的认知缺陷的治疗中使用它们的制药组合物和方法。